Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Oppenheimer analyst Jay Olson maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).